UBS lowered the firm’s price target on Bath & Body Works to $32 from $36 and keeps a Neutral rating on the shares following the Q2 report. The firm sees limited upside to the Street’s fiscal 2025 earnings estimates. Bath & Body has few levers to drive margin upside and new CEO Daniel Heaf’s wholesale channel expansion strategy could further pressure its EBIT margin expansion, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Positive Outlook for Bath & Body Works Amid Robust Sales and Strategic Innovations
- Bath & Body Works price target raised to $32 from $30 at Barclays
- Bath & Body Works Reports Strong Q2 2025 Results
- Bath & Body Works: Buy Rating Affirmed Amid Strategic Growth Potential and Overcoming Challenges
- Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz